

# Acute mental health service use is increased in rheumatoid arthritis and ankylosing spondylitis: a population-based cohort study

Bindee Kuriya<sup>ID</sup>, Vivian Tia, Jin Luo, Jessica Widdifield, Simone Vigod and Nigil Haroon

## Abstract

**Background:** Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are associated with mental illness. Whether acute mental health (MH) service utilization (i.e. emergency visits or hospitalizations) is increased in RA or AS is not known.

**Methods:** Two population-based cohorts were created where individuals with RA ( $n=53,240$ ) or AS ( $n=13,964$ ) were each matched by age, sex, and year to unaffected comparators (2002–2016). Incidence rates per 1000 person-years (PY) were calculated for a first MH emergency department (ED) presentation or MH hospitalization. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated, adjusting for demographic, clinical, and health service use variables.

**Results:** Individuals with RA had higher rates of ED visits [6.59/1000 person-years (PY) *versus* 4.39/1000 PY in comparators] and hospitalizations for MH [3.11/1000 PY *versus* 1.80/1000 PY in comparators]. Higher rates of ED visits [7.92/1000 PY *versus* 5.62/1000 PY in comparators] and hospitalizations [3.03/1000 PY *versus* 1.94/1000 PY in comparators] were also observed in AS. Overall, RA was associated with a 34% increased risk for MH hospitalization (HR 1.34, 95% CI 1.22–1.47) and AS was associated with a 36% increased risk of hospitalization (HR 1.36, 95% CI 1.12–1.63). The risk of ED presentation was attenuated, but remained significant, after adjustment in both RA (HR 1.08, 95% CI 1.01–1.15) and AS (HR 1.14, 95% CI 1.02–1.28).

**Conclusions:** RA and AS are both independently associated with a higher rate and risk of acute ED presentations and hospitalizations for mental health conditions. These findings underscore the need for routine evaluation of MH as part of the management of chronic inflammatory arthritis. Additional research is needed to identify the underlying individual characteristics, as well as system-level variation, which may explain these differences, and to help plan interventions to make MH service use more responsive to the needs of individuals living with RA and AS.

**Keywords:** ankylosing spondylitis, cohort study, health services research, mental health, rheumatoid arthritis

Received: 3 December 2019; revised manuscript accepted: 29 February 2020.

## Introduction

Individuals with inflammatory arthritis, including rheumatoid arthritis (RA) and ankylosing spondylitis (AS), frequently experience psychological distress. The adaptation to living with a chronic illness and physical symptoms of pain and fatigue can contribute to unpleasant feelings or emotions.<sup>1</sup> Systemic inflammation may have direct effects on regulating

mood and emotion.<sup>2</sup> Negative psychological symptoms may also arise from adverse effects of disease modifying antirheumatic drugs and corticosteroids that are used to treat RA and AS.<sup>1,3</sup> It follows that rates of mental illness including depression, anxiety and substance abuse are substantially higher in both RA and AS compared with the general population.<sup>3,4</sup>

*Ther Adv Musculoskel Dis*

2020, Vol. 12: 1–11

DOI: 10.1177/  
1759720X20921710

© The Author(s), 2020.  
Article reuse guidelines:  
sagepub.com/journals-  
permissions

Correspondence to:

**Bindee Kuriya**  
Division of Rheumatology,  
Sinai Health System,  
University of Toronto,  
60 Murray Street, Room  
2-008, Toronto, Ontario  
M5T 3L9, Canada  
[bindee.kuriya@sinaihealthsystem.ca](mailto:bindee.kuriya@sinaihealthsystem.ca)

**Vivian Tia**  
Schulich School of  
Medicine & Dentistry,  
Western University,  
London, Ontario, Canada

**Jin Luo**  
ICES, Toronto, Ontario,  
Canada

**Jessica Widdifield**  
ICES, Toronto, Ontario,  
Canada

Sunnybrook Research  
Institute, Holland  
Musculoskeletal Research  
Program, Toronto, Ontario,  
Canada

Institute of Health Policy,  
Management & Evaluation,  
University of Toronto,  
Toronto, Ontario, Canada

**Simone Vigod**  
ICES, Toronto, Ontario,  
Canada

Institute of Health Policy,  
Management & Evaluation,  
University of Toronto,  
Toronto, Ontario, Canada

Department of Psychiatry,  
Women's College Hospital  
and Women's College  
Research Institute,  
University of Toronto,  
Toronto, Ontario, Canada

**Nigil Haroon**  
Krembil Research  
Institute, University Health  
Network, University of  
Toronto, Toronto, Ontario,  
Canada

Mental health (MH) conditions are important to recognize and treat because their effects extend beyond just the mental illness itself.<sup>5</sup> Comorbid mental illness is associated with poor arthritis outcomes: higher rates of disability, medication non-adherence, and lower likelihood of achieving and maintaining clinical remission.<sup>5,6</sup> Therefore, mental illness may be a potentially modifiable determinant of arthritis prognosis and is important to identify and manage.<sup>7</sup>

Similar to the disease course of RA or AS that is often punctuated by acute flares, mental illness symptoms can be episodic or fluctuate and make identification of severe mental illness challenging. However, it is important to differentiate acute and chronic mental illness as they may require different systems and approaches to care.<sup>8,9</sup> The use of acute medical services may also provide insights into potential gaps in ambulatory rheumatology care.<sup>9,10</sup> For example, an emergency department (ED) presentation for a mental illness may be the first time an individual is presenting with a MH concern or be an exacerbation of their existing mental illness.<sup>10,11</sup> In addition, it may indicate inadequate recognition before a “crisis,” stemming from poor access to primary care where most mental illness is diagnosed, treated, and referred for specialty services.<sup>9,11</sup> An acute hospitalization, that may follow an ED visit, typically reflects the severity of an individual’s mental health status and/or need for urgent therapy.<sup>8</sup> Furthermore, the impact of an acute mental illness added to a physically disabling condition like RA or AS could have multiplicative health effects.<sup>12</sup> To the best of the authors’ knowledge, the use of acute mental health services in either RA or AS have not been examined comprehensively.

This study aimed to fill this knowledge gap. Our objective was to estimate acute mental health service use following a diagnosis of RA or AS. Understanding the extent of ED visits and hospitalizations as a point of contact for mental health care in RA and AS would be an important first step to help plan services and targeted interventions for these complex inflammatory conditions.

## Patients and methods

### Study design and data sources

We conducted two retrospective, population-based cohort studies of subjects with each of RA ( $n=53,240$ ) or AS ( $n=13,964$ ) matched to

population comparators between April 1, 2002 and March 31, 2016.

We used the following health administrative databases for the province of Ontario, Canada: (1) The Registered Persons Database identified residents eligible for the universal Ontario Health Insurance Plan (OHIP), and information on date of birth, sex, and postal code (to determine urban *versus* rural residence) was obtained; (2) The Canadian Institutes of Health Information Discharge Abstract Database was used to identify hospital admissions and the most responsible diagnoses for the acute hospitalization, according to the International Classification of Diseases (ICD) 10th revision diagnosis codes, the Canadian Classification of Procedures, and the Canadian Classification of Health Interventions codes; (3) The Ontario Mental Health Reporting System provided clinical and administrative data on all mental health hospitalizations from 2005 onward; (4) the National Ambulatory Care Reporting System identified all ED visits and; (5) The OHIP Claims History Database identified diagnoses and procedures associated with physician billing claims. All datasets were de-identified and linked using unique encoded identifiers and analyzed at ICES ([www.ices.on.ca](http://www.ices.on.ca)). The use of data in this project was authorized under section 45 of Ontario’s Personal Health Information Protection Act, which does not require review by a Research Ethics Board.

### Study population

Two parallel matched cohorts were created. In the first, we compared individuals with incident RA with a matched, non-RA comparator cohort. In the second, we compared individuals with incident AS with a separate matched non-AS comparator cohort.

All subjects (RA, AS, and comparators) were excluded if they had any mental illness or addiction encounter with a family physician or psychiatrist (by outpatient billing codes ICD-9: 290-315), hospitalization, or ED visit for a mental health diagnosis in the two years prior to RA or AS diagnosis.<sup>13</sup>

We identified an inception RA cohort within the Ontario Rheumatoid Arthritis Dataset (ORAD), from April 1, 2002 to March 31, 2014. ORAD is a validated population-based research database of all Ontarians with RA.<sup>14,15</sup> Patients were excluded if they had missing age or sex, AS diagnosis, or

other systemic autoimmune rheumatic disorder (SARD) in the 2 years before RA diagnosis. The comparison cohort comprised Ontarians without RA, matched 4:1 on age ( $\pm 365$  days), sex, and calendar year. Comparators were randomly assigned an index date of the corresponding RA cases by calendar year and quarter.

For the second matched cohort, we used a published algorithm to identify an incident AS cohort.<sup>16</sup> Patients were excluded if missing age or sex, RA, or any SARD in the 2 years before AS diagnosis. The comparison cohort included Ontarians without AS, matched 4:1 to AS patients on age ( $\pm 365$  days), sex, and calendar year. Index date for comparators was randomly assigned to match AS cases by calendar year and quarter.

Patients were followed from cohort entry date until migration, death, end of study period (31 March 2016), or outcome occurrence, whichever came first.

#### *Acute mental health care outcomes*

We had two primary outcomes of interest subsequent to an RA or AS diagnosis: (1) A first ED presentation for mental illness but not requiring admission to hospital or (2) a first hospitalization attributable to mental illness. These were considered independent events and outcomes were identified by validated diagnostic codes, following the approach of the Mental Health and Addictions Scorecard Evaluation Framework research team at ICES.<sup>17</sup> The most responsible mental illness diagnosis from the ED or hospital discharge record was summarized according to psychiatric diagnostic categories (Supplementary Table 1).

#### *Exposure and covariates*

Our main exposures of interest were arthritis diagnosis (RA or AS). In addition to age and sex, we ascertained patient residence (urban *versus* rural), socioeconomic status, and ethnicity (Chinese, South Asian, and Other) with a validated surname algorithm.<sup>18</sup> Baseline comorbidities were determined using a 24-month look back window from time of cohort entry. Validated algorithms were used to identify hypertension,<sup>19</sup> diabetes,<sup>20</sup> inflammatory bowel disease (IBD),<sup>21</sup> coronary artery disease and acute myocardial infarction,<sup>22</sup> cerebrovascular accident,<sup>23</sup> chronic obstructive pulmonary disease (COPD)/asthma,<sup>24</sup> renal

failure,<sup>25</sup> cancer, upper gastrointestinal bleed, osteoarthritis, osteoporosis, infection, or psoriasis.<sup>16</sup> We measured overall comorbidity severity using the Charlson Comorbidity Index, which reflects relevant diagnoses during an episode of care as an inpatient.<sup>26,27</sup> We also examined non-mental health care use (number of outpatient visits, rheumatology visits, hospitalizations, ED visits) in the 2 years prior to index date.

#### *Statistical analysis*

We used standardized differences to compare baseline characteristics of individuals with RA, AS, and matched comparators. For each outcome, we calculated overall sex- and age-stratified incidence rates (IR) per 1000 person-years (PY) with four age categories (<20, 21–44, 45–64, 65+ years).

We conducted separate Cox proportional hazards models to estimate hazard ratios (HRs) and 95% confidence intervals (CI) for RA and AS for each outcome of ED visit or hospitalization. Age and sex were *a priori* selected as clinically important confounders, and were used as matching criteria, so were not further entered into Cox models. We generated unadjusted HRs for the association between RA or AS and each acute mental illness outcome, separately. Then, we constructed univariate models including all baseline variables. The full multivariable models adjusted for previous non-mental health care use regardless of *p*-value, as well as any variables with *p* < 0.05 in the univariate models. All analyses were conducted using SAS statistical software (version 9.3; SAS Institute, Cary, NC).

#### **Results**

A total of 53,240 individuals with RA (matched to 212,960 unaffected comparators) and 13,964 individuals with AS (matched to 55,856 unaffected comparators) with no previous history of MH care use were included in the analyses (Supplementary Figures 1 and 2). Baseline characteristics of the cohorts are shown in Table 1. The mean age of RA patients was 56.5 years (SD, 17.1) and 67% were female. Patients with AS were younger, with a mean age of 46.4 years (SD, 16.6) and 43% were female. The average duration of follow up in both cohorts was 7 years. Compared with their matched comparators, a greater number of comorbid conditions was observed in both RA patients (osteoarthritis,

**Table 1.** Baseline characteristics of individuals with RA, AS, or matched unaffected comparators with no prior history of mental illness.

Variable	RA n=53,240	Non-RA comparator n=212,960	Standardized difference	AS n=13,964	Non-AS comparator n=55,856	Standardized difference
<b>Demographics</b>						
Age at index date, mean $\pm$ SD	56.5 $\pm$ 17.1	56.5 $\pm$ 17.1	0	46.4 $\pm$ 16.6	46.4 $\pm$ 16.6	0
Female sex, n (%)	35,702 (67.1)	142,808 (67.1)	0	6064 (43.4)	24,256 (43.4)	0
Rural residence, n (%)	7743 (14.5)	25,771 (12.1)	0.07	1608 (11.5)	6216 (11.1)	0.01
Income quintile, n (%)						
1 (lowest)	9878 (18.6)	41,582 (19.5)	0.02	2359 (16.9)	11,275 (20.2)	0.08
2	10,777 (20.2)	42,800 (20.1)	0	2595 (18.6)	11,237 (20.1)	0.04
3	10,930 (20.5)	41,616 (19.5)	0.02	2715 (19.4)	11,038 (19.8)	0.01
4	10,907 (20.5)	42,697 (20.0)	0.01	3056 (21.9)	11,163 (20.0)	0.05
5	10,748 (20.2)	44,265 (20.8)	0.01	3239 (23.2)	11,143 (19.9)	0.08
Ethnicity, n (%)						
Chinese	1279 (2.4)	12,943 (6.1)	0.18	709 (5.1)	3,677 (6.6)	0.06
South Asian	1980 (3.7)	6820 (3.2)	0.03	434 (3.1)	2070 (3.7)	0.03
Other	49,981 (93.9)	193,197 (90.7)	0.12	12,821 (91.8)	50,109 (89.7)	0.07
<b>Comorbidities, n (%)</b>						
Charlson Comorbidity Index						
0	48,895 (91.8)	202,214 (95.0)	0.13	13,211 (94.6)	54,237 (97.1)	0.13
1	2131 (4.0)	4569 (2.1)	0.11	426 (3.1)	725 (1.3)	0.12
2	1260 (2.4)	3440 (1.6)	0.05	207 (1.5)	517 (0.9)	0.05
3+	954 (1.8)	2737 (1.3)	0.04	120 (0.9)	377 (0.7)	0.02
Osteoarthritis	15,200 (28.5)	11,602 (5.4)	0.65	2164 (15.5)	1658 (3.0)	0.44
Osteoporosis	1153 (2.2)	3286 (1.5)	0.05	237 (1.7)	370 (0.7)	0.10
Chronic Obstructive Pulmonary Disease	6970 (13.1)	18,334 (8.6)	0.14	984 (7.0)	2791 (5.0)	0.09
Coronary Artery Disease	2807 (5.3)	7912 (3.7)	0.08	434 (3.1)	1190 (2.1)	0.06
Myocardial Infarction	502 (0.9)	1351 (0.6)	0.03	68 (0.5)	203 (0.4)	0.02
Cardiovascular Disease	114 (0.2)	447 (0.2)	0	17 (0.1)	51 (0.1)	0.01
Hypertension	21,674 (40.7)	70,533 (33.1)	0.16	3663 (26.2)	11,082 (19.8)	0.15
Acute Renal Failure	594 (1.1)	1170 (0.5)	0.06	107 (0.8)	195 (0.3)	0.06
Chronic Renal Failure	1284 (2.4)	2757 (1.3)	0.08	224 (1.6)	433 (0.8)	0.08
Diabetes Mellitus	8161 (15.3)	27,304 (12.8)	0.07	1473 (10.5)	4622 (8.3)	0.08

Continued

**Table 1.** (Continued)

Variable	RA n=53,240	Non-RA comparator n=212,960	Standardized difference	AS n=13,964	Non-AS comparator n=55,856	Standardized difference
Dementia	177 (0.3)	645 (0.3)	0.01	31 (0.2)	59 (0.1)	0.03
Malignancy	3539 (6.6)	13,088 (6.1)	0.02	590 (4.2)	1,827 (3.3)	0.05
Upper Gastrointestinal Bleed	142 (0.3)	249 (0.1)	0.03	17 (0.1)	43 (0.1)	0.01
Infection	23,051 (43.3)	58,943 (27.7)	0.33	6049 (43.3)	14,197 (25.4)	0.38
Inflammatory Bowel Disease	827 (1.6)	1064 (0.5)	0.10	778 (5.6)	230 (0.4)	0.31
Psoriasis	643 (1.2)	393 (0.2)	0.12	399 (2.9)	81 (0.1)	0.22
<b>Non-Mental Health Care Utilization</b>						
Physician visits, n (%)	52,290 (98.2)	163,790 (76.9)	0.68	13,830 (99.0)	39,476 (70.7)	0.86
Physician visits, mean $\pm$ SD	29.2 $\pm$ 26.92	15.3 $\pm$ 20.9	0.57	26.7 $\pm$ 25.4	11.01 $\pm$ 18.02	0.71
Rheumatology visits, n (%)	18,196 (34.2)	8602 (4.0)	0.83	4967 (35.6)	1537 (2.8)	0.92
Rheumatology visits, mean $\pm$ SD	1.31 $\pm$ 3.32	0.09 $\pm$ 0.67	0.51	1.37 $\pm$ 3.77	0.08 $\pm$ 0.86	0.47
Hospitalizations, n (%)	8388 (15.8)	18,862 (8.9)	0.21	1735 (12.4)	3551 (6.4)	0.21
Hospitalizations, mean $\pm$ SD	0.24 $\pm$ 0.70	0.13 $\pm$ 0.51	0.18	0.18 $\pm$ 0.62	0.09 $\pm$ 0.41	0.18
Emergency Department visit, n (%)	23,586 (44.3)	49,702 (23.3)	0.45	6068 (43.5)	12,432 (22.3)	0.46
Emergency Department visit, mean $\pm$ SD	1.01 $\pm$ 1.88	0.44 $\pm$ 1.23	0.36	0.99 $\pm$ 2.07	0.41 $\pm$ 1.16	0.35
AS, ankylosing spondylitis; RA, rheumatoid arthritis.						


COPD, hypertension, IBD, psoriasis) and AS patients (osteoarthritis, osteoporosis, hypertension, infections, IBD, psoriasis). RA and AS patients had greater non-mental health care use, including outpatient physician visits, hospitalizations, and non-mental health related ED visits compared with matched subjects (Table 1).

The overall crude incidence rate of an ED visit for mental illness following RA diagnosis was 6.59/1000 PY compared with 4.39/1000 PY in non-RA comparators. Median time-to-first ED visit was 6.4 years among RA subjects and 7.4 years for comparators. AS subjects also had higher rates of an ED visit (7.92/1000 PY) compared with non-AS comparators (5.62/1000 PY) and this occurred a median of 6.9 years following AS diagnosis and 7.2 years for comparators. The incidence of an ED visit was higher in RA and AS

*versus* comparators in all analyses stratified by age, and sex (Table 2).

In the RA, AS, and comparator groups, risk for an ED visit was higher in men and in subjects less than 20 years of age (data not shown). ED visits were most common for anxiety and adjustment disorders, followed by substance-related disorders, mood, and affective disorders, and lastly due to psychotic disorders (Figure 1a and b).

The incidence rates for a first MH hospitalization were also higher in subjects with RA (3.11/1000 PY *versus* 1.80/1000 PY in comparators) and AS (3.03/1000 PY *versus* 1.94/1000 PY) (Table 2). Median time to hospitalization was 6.5 years after RA diagnosis and 7 years after AS diagnosis. Hospitalization was most common in men and younger subjects (Table 2). Mood and affective



**Figure 1.** Incidence rate per 1000 person-years for acute mental illness encounters in RA, AS, and unaffected matched comparators. Rates are presented for emergency department (ED) visits (a and b) and hospitalizations (c and d), according to psychiatric diagnostic category.

disorders, followed by substance-related disorders, were the most responsible diagnoses leading to an acute hospitalization (Figure 1b and c).

In final multivariable analyses, the risk of an acute ED presentation for mental illness was attenuated but remained statistically significant after adjustment for income, ethnicity, comorbidities, and previous non-mental health care use in both RA (adjusted HR 1.08, 95% CI 1.01–1.15) and AS (adjusted HR 1.14, 95% CI 1.02–1.28, Table 3). RA was also independently associated with a 34% increased risk of acute mental illness hospitalization (multivariate adjusted HR 1.34, 95% CI 1.22–1.47). Similarly, AS was associated with a 36% increased risk of hospitalization compared with non-AS subjects (multivariate adjusted HR 1.36, 95% CI 1.12–1.643, Table 3).

### Discussion

To the best of the authors' knowledge, this is the first population-based study to examine acute MH care utilization among individuals with RA or AS. RA and AS were both independently

associated with higher rates and risk of emergency department presentations for mental illness. A key finding was a significantly increased risk of acute hospitalization associated with RA and AS, particularly for mood disorders, anxiety, and substance-related disorders. Our findings indicate that emergency service use is a more frequent point of contact with the mental health system for individuals with inflammatory arthritis, compared with those without RA or AS. While this may suggest a higher acuity or severity of mental illness, this may also represent system or individual level barriers in access to outpatient care. While we cannot answer this with our data alone, future work is needed to explore if inequities in outpatient mental health, lower quality, or effectiveness of care when it is accessed are possible contributors to the high rates of emergency mental health care we observed.

The finding that acute mental health care service use differed by age and sex is of interest. Younger age and men with RA or AS had higher rates of ED visits and hospitalizations compared with women. Studies of the general population, and

**Table 2.** Crude incidence rates, per 1000 patient years (PY) for an ED visit or acute mental illness hospitalization among the study sample.

	RA <i>n</i> = 53,240		Non-RA <i>n</i> = 212,960		AS <i>n</i> = 13,964		Non-AS <i>n</i> = 55,856	
	<i>n</i>	Rate	<i>n</i>	Rate	<i>n</i>	Rate	<i>n</i>	Rate
<b>ED Visit Rate</b>								
Overall	2426	6.59	6679	4.39	808	7.92	2316	5.62
Female	1604	6.42	4478	4.35	308	7.01	780	4.41
Male	822	6.95	2,201	4.47	500	8.61	1536	6.54
Age group, years								
<20	273	18.99	1017	17.59	128	23.07	287	12.89
21–44	765	9.43	1824	5.60	422	9.14	1227	6.64
45–64	848	5.23	2302	3.49	187	5.02	592	3.96
65+	540	4.89	1536	3.20	71	5.44	210	3.83
<b>Hospitalization Rate</b>								
Overall	1,146	3.11	2744	1.80	309	3.03	797	1.94
Female	710	2.84	1739	1.69	114	2.60	295	1.67
Male	436	3.69	1005	2.04	195	3.36	502	2.14
Age group, years								
<20	273	5.84	204	3.53	53	9.55	102	4.58
21–44	765	2.65	548	1.68	135	2.93	306	1.65
45–64	848	2.20	810	1.23	75	2.01	238	1.59
65+	540	4.43	1182	2.45	46	3.53	151	2.75

AS, ankylosing spondylitis; ED, emergency department; RA, rheumatoid arthritis.

**Table 3.** Unadjusted and adjusted hazard ratios (HR) with 95% confidence intervals (CI) for an emergency department (ED) visit or acute hospitalization for mental illness among individuals with RA or AS.

	ED visit			Hospitalization		
	Unadjusted HR (95% CI)	Adjusted HR <sup>a</sup> (95% CI)	Adjusted HR <sup>b</sup> (95% CI)	Unadjusted HR (95% CI)	Adjusted HR <sup>a</sup> (95% CI)	Adjusted HR <sup>b</sup> (95% CI)
RA	1.47 (1.38–1.53)	1.08 (1.01–1.16)	1.08 (1.01–1.15)	1.74 (1.59–1.90)	1.38 (1.25–1.54)	1.34 (1.22–1.47)
AS	1.57 (1.41–1.74)	1.19 (1.05–1.36)	1.14 (1.02–1.28)	1.71 (1.44–2.03)	1.27 (1.02–1.59)	1.36 (1.12–1.63)

Model <sup>a</sup> adjusted for all covariates listed in Table 1.  
Model <sup>b</sup> adjusted for socioeconomic status, ethnicity, comorbidities (chronic obstructive pulmonary disease, diabetes, hypertension, infection), and previous non-mental health care use (physician or ED visit).

those with chronic illness, have identified a similar trend of ED presentations for psychiatric disorders to be more common in adolescent and young adult men, but this has not been verified in

an inflammatory arthritis population to our knowledge.<sup>28–30</sup> Interestingly, a study specific to general health care use in RA demonstrated that women had higher ambulatory physician use, but ER visits and hospitalizations were more common in men, as our data support.<sup>31</sup> Our findings suggest that men with RA and AS may be particularly vulnerable to crisis situations prompting emergency care, or it may relate to the acuity and manner of the presentation (e.g. substance-related disorder, overdose), which is best managed in an acute care setting.<sup>29</sup> Future work might explore whether there are also age and sex differences in receipt of outpatient MH visits, which may account for these imbalances observed in acute care settings.

On average, the first ED visit or hospitalization occurred approximately 7 years following RA or AS diagnosis. While this is limited by the duration of follow-up available in the study, the observed timing of a first acute MH presentation contrasts non-mental health care use that has been reported to be highest in the first year following arthritis diagnosis and declines steadily thereafter.<sup>31</sup> The reasons for this difference in health care use may be postulated. At the system level, the initial focus after RA or AS diagnosis may be on the “window of opportunity” where early and aggressive disease-modifying antirheumatic disease (DMARD) therapy can significantly improve arthritis outcomes. In this setting, mental symptoms, even if severe, may be prioritized as lower than physical concerns of pain and disability.<sup>7,32</sup> There may also be little or no time devoted to MH screening, either due to lack of training or expertise by the rheumatologist or the belief that other health care providers would better address MH concerns.<sup>32,33</sup> At the patient level, mental illness may appear clinically very similar to symptoms of RA or AS, and can be misattributed to active arthritis rather than comorbid mental illness.<sup>32</sup> Importantly, many patients face stigma associated with disclosing feelings of depression, anxiety, or admission of substance misuse or dependency.<sup>32</sup> These barriers may prevent timely diagnosis and treatment of mental illness that eventually reaches a “crisis” threshold, or there may be inadequacies in how outpatient medical and MH services are integrated.<sup>34</sup> Multiple system and patient-level barriers are likely responsible for the higher acute mental health care encounters observed in RA and AS, but the implication of our findings is that surveillance for mental illness should be regular and frequent because mental illness sequelae may occur at any point along the disease continuum.

The strengths of our study include the large sample sizes and inclusion of a population with universal health care coverage for emergency and hospital services. This population is reflective of real-world clinical practice and enhances generalizability of our findings to similar health care settings. We also used validated algorithms to reduce misclassification of our exposure and outcome definitions.

Our study was limited by the clinical detail available in health administrative data. Information on RA or AS disease severity could not be ascertained, although inconsistent results have been reported about the association between arthritis disease activity and mental illness symptom severity.<sup>35,36</sup> We were not able to assess the quality or appropriateness of care received and did not assess repeat admissions. Our findings may be an underestimate of the true rate of mental illness as we restricted our population to those with no prior history of mental illness health care encounters. We did not have information on personality traits or perceived impact of illness that could influence the decision to seek out emergency care. Underestimates of acute mental illness may have occurred if the underlying rheumatic disease was listed as the most responsible diagnosis instead. We did not explore time-varying factors such as mental health diagnoses, new comorbidities, or health care visits in the interval after RA or AS diagnosis that may have influenced emergency care.

Finally, details on disease modifying antirheumatic drugs, psychiatric medications, or medications that may be misused (e.g. opioids) were lacking as a minority of patients were over the age of 66 for whom prescription data are universally available. Our findings indicate that substance abuse disorders were the second most common reason for ED visits and hospital admission. We cannot determine whether this was related to an abuse of medications intended for medical use, driven by alcohol, illicit drug use, or a combination of all. Further evaluation is necessary to help inform strategies for diversion of substance abuse in this population.

In conclusion, RA and AS are both associated with an increased acute mental health care utilization. These findings suggest that screening for mental illness should be considered in the management of chronic inflammatory arthritis. Additional research is needed to identify the types



and extent of barriers facing individuals with RA and AS that may contribute to acute mental illness presentations. This knowledge can help plan interventions aimed at prevention but more importantly, make existing mental health services more responsive to the needs of our patients.

### Acknowledgements

This study was supported by ICES ([www.ices.on.ca](http://www.ices.on.ca)), which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). The opinions, results, and conclusions reported in this paper are those of the authors and are independent from the funding sources. No endorsement by ICES or the Ontario MOHLTC is intended or should be inferred. Parts of this material are based on data and/or information compiled and provided by CIHI. However, the analyses, conclusions, opinions, and statements expressed in the material are those of the author(s), and not necessarily those of CIHI.

### Author contributions

The corresponding author affirms that all authors (BK, VT, JL, JW, SV, NH) contributed to the planning, conduct, and reporting of the work described in the article.

### Conflict of interest statement

The authors declare that there is no conflict of interest.

### Ethics approval and consent to participate

The use of data in this project was authorized under section 45 of Ontario's Personal Health Information Protection Act, which does not require review by a Research Ethics Board.

### Funding

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Author BK was supported by The Canadian Rheumatology Association/The Arthritis Society Clinician Investigator Award (CCT-015-18) and study funding was provided by the Division of Rheumatology Pfizer Research Chair, University of Toronto and the Sinai Health System Department of Medicine Clinical Research Support Program. The funders had no role in the design, conduct, analysis or reporting of this study.

### ORCID iD

Bindee Kuriya  <https://orcid.org/0000-0003-3370-0006>

### Supplemental material

Supplemental material for this article is available online.

### References

1. Nicassio PM. Arthritis and psychiatric disorders: disentangling the relationship. *J Psychosom Res* 2010; 68: 183–185.
2. Dantzer R, O'Connor JC, Freund GG, *et al.* From inflammation to sickness and depression: when the immune system subjugates the brain. *Nat Rev Neurosci* 2008; 9: 46–56.
3. Euesden J, Matcham F, Hotopf M, *et al.* The relationship between mental health, disease severity, and genetic risk for depression in early rheumatoid arthritis. *Psychosom Med* 2017; 79: 638–645.
4. Wu JJ, Penfold RB, Primatesta P, *et al.* The risk of depression, suicidal ideation and suicide attempt in patients with psoriasis, psoriatic arthritis or ankylosing spondylitis. *J Eur Acad Dermatol Venereol* 2017; 31: 1168–1175.
5. Margaretten M, Julian L, Katz P, *et al.* Depression in patients with rheumatoid arthritis: description, causes and mechanisms. *Int J Clin Rheumatol* 2011; 6: 617–623.
6. Michelsen B, Kristianslund EK, Sexton J, *et al.* Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR-DMARD study. *Ann Rheum Dis* 2017; 76: 1906–1910.
7. Withers MH, Gonzalez LT and Karpouzas GA. Identification and treatment optimization of comorbid depression in rheumatoid arthritis. *Rheumatol Ther* 2017; 4: 281–291.
8. Hensel JM, Taylor VH, Fung K, *et al.* Acute care use for ambulatory care-sensitive conditions in high-cost users of medical care with mental illness and addictions. *Can J Psychiatry* 2018; 63: 706743717752880.
9. Anderson KK, Fuhrer R, Wynant W, *et al.* Patterns of health services use prior to a first diagnosis of psychosis: the importance of primary care. *Soc Psychiatry Psychiatr Epidemiol* 2013; 48: 1389–1398.
10. Gill PJ, Saunders N, Gandhi S, *et al.* Emergency department as a first contact for mental health problems in children and youth. *J Am Acad Child Adolesc Psychiatry* 2017; 56: 475–482.e4.
11. Saunders NR, Gill PJ, Holder L, *et al.* Use of the emergency department as a first point of contact

- for mental health care by immigrant youth in Canada: a population-based study. *CMAJ* 2018; 190: E1183–E1191.
12. Parrish E. Comorbidity of mental illness and chronic physical illness: a diagnostic and treatment conundrum. *Perspect Psychiatr Care* 2018; 54: 339–340.
  13. Steele LS, Glazier RH, Lin E, *et al.* Using administrative data to measure ambulatory mental health service provision in primary care. *Med Care* 2004; 42: 960–965.
  14. Widdifield J, Bernatsky S, Paterson JM, *et al.* Accuracy of Canadian health administrative databases in identifying patients with rheumatoid arthritis: a validation study using the medical records of rheumatologists. *Arthritis Care Res (Hoboken)* 2013; 65: 1582–1591.
  15. Widdifield J, Bombardier C, Bernatsky S, *et al.* An administrative data validation study of the accuracy of algorithms for identifying rheumatoid arthritis: the influence of the reference standard on algorithm performance. *BMC Musculoskeletal Disord* 2014; 15: 216.
  16. Haroon NN, Paterson JM, Li P, *et al.* Patients with ankylosing spondylitis have increased cardiovascular and cerebrovascular mortality: a population-based study. *Ann Intern Med* 2015; 163: 409–416.
  17. Mental Illness Hospitalization. Toronto: Canadian institute for health information, <http://indicatorlibrary.cihi.ca/display/HSPIL/Mental+Illness+Hospitalization> (2018, accessed 26 September 2018).
  18. Shah BR, Chiu M, Amin S, *et al.* Surname lists to identify South Asian and Chinese ethnicity from secondary data in Ontario, Canada: a validation study. *BMC Med Res Methodol*, 2010; 10: 42.
  19. Tu K, Campbell NR, Chen ZL, *et al.* Accuracy of administrative databases in identifying patients with hypertension. *Open Med* 2007; 1: e18–e26.
  20. Hux JE, Ivis F, Flintoft V, *et al.* Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. *Diabetes Care* 2002; 25: 512–516.
  21. Benchimol EI, Guttmann A, Mack DR, *et al.* Validation of international algorithms to identify adults with inflammatory bowel disease in health administrative data from Ontario, Canada. *J Clin Epidemiol* 2014; 67: 887–896.
  22. Tu K, Mitiku T, Guo H, *et al.* Myocardial infarction and the validation of physician billing and hospitalization data using electronic medical records. *Chronic Dis Can* 2010; 30: 141–146.
  23. Tu K, Wang M, Young J, *et al.* Validity of administrative data for identifying patients who have had a stroke or transient ischemic attack using EMERALD as a reference standard. *Can J Cardiol* 2013; 29: 1388–1394.
  24. Gershon AS, Wang C, Guan J, *et al.* Identifying patients with physician-diagnosed asthma in health administrative databases. *Can Respir J* 2009; 16: 183–188.
  25. Fleet JL, Dixon SN, Shariff SZ, *et al.* Detecting chronic kidney disease in population-based administrative databases using an algorithm of hospital encounter and physician claim codes. *BMC Nephrol* 2013; 14: 81.
  26. D’Hoore W, Bouckaert A and Tilquin C. Practical considerations on the use of the Charlson comorbidity index with administrative data bases. *J Clin Epidemiol* 1996; 49: 1429–1433.
  27. Sundararajan V, Henderson T, Perry C, *et al.* New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. *J Clin Epidemiol* 2004; 57: 1288–1294.
  28. Bethell J, Bondy SJ, Lou WY, *et al.* Emergency department presentations for self-harm among Ontario youth. *Can J Public Health* 2013; 104: e124–e130.
  29. Ranney ML, Locci N, Adams EJ, *et al.* Gender-specific research on mental illness in the emergency department: current knowledge and future directions. *Acad Emerg Med* 2014; 21: 1395–1402.
  30. Abernathy K, Zhang J, Mauldin P, *et al.* Acute care utilization in patients with concurrent mental health and complex chronic medical conditions. *J Prim Care Community Health* 2016; 7: 226–233.
  31. Hanly JG, Thompson K and Skedgel C. A longitudinal study of ambulatory physician encounters, emergency room visits, and hospitalizations by patients with rheumatoid arthritis: a 13-year population health study. *J Rheumatol* 2017; 44: 1421–1428.
  32. Withers M, Moran R, Nicassio P, *et al.* Perspectives of vulnerable US Hispanics with rheumatoid arthritis on depression: awareness, barriers to disclosure and treatment options. *Arthritis Care Res (Hoboken)* 2015; 67: 484–492.
  33. Matcham F, Rayner L, Steer S, *et al.* The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. *Rheumatology (Oxford)* 2013; 52: 2136–2148.
  34. Fradgley EA, Paul CL and Bryant J. A systematic review of barriers to optimal

- outpatient specialist services for individuals with prevalent chronic diseases: what are the unique and common barriers experienced by patients in high income countries? *Int J Equity Health* 2015; 14: 52.
35. Kuriya B, Joshi R, Movahedi M, *et al.* High disease activity is associated with self-reported depression and predicts persistent depression in early rheumatoid arthritis: results from the Ontario best practices research initiative. *J Rheumatol* 2018; 45: 1101–1108.
36. Santos EF, Duarte CM, Ferreira RO, *et al.* Multifactorial explanatory model of depression in patients with rheumatoid arthritis: a structural equation approach. *Clin Exp Rheumatol* 2019; 37: 641–648.

Visit SAGE journals online  
[journals.sagepub.com/  
home/tab](http://journals.sagepub.com/home/tab)

 SAGE journals